Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients
Severson,T.,Zhu,Y.,Prekovic,S.,Schuurman,K.,Nguyen,H.,Brown,L.,Hakkola,S.,Kim,Y.,Kneppers,J.,Linder,S.,Stelloo,S.,Lieftink,C.,van der Heijden,M.,Nykter,M.,van der Noort,V.,Sanders,J.,Morris,B.,Jenster,G.,van Leenders,G.,Pomerantz,M.,Freedman,M.,Beijersbergen,R.,Urbanucci,A.,Wessels,L.,Corey,E.,Zwart,W.,Bergman,A.
DOI: https://doi.org/10.1101/2023.02.24.23286403
2023-02-26
MedRxiv
Abstract:Androgen Receptor (AR) signaling inhibitors, including enzalutamide, are treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), but resistance inevitably develops. Using metastatic samples from a prospective phase II clinical trial, we epigenetically profiled enhancer/promoter activities with H3K27ac chromatin immunoprecipitation followed by sequencing, before and after AR-targeted therapy. We identified a distinct subset of H3K27ac-differentially marked regions that associated with treatment responsiveness. These data were successfully validated in mCRPC patient-derived xenograft models (PDX). In silico analyses revealed HDAC3 as a critical factor that can drive resistance to hormonal interventions, which we validated in vitro. Using cell lines and mCRPC PDX tumors in vitro, we identified drug-drug synergy between enzalutamide and the pan-HDAC inhibitor vorinostat, providing therapeutic proof-of-concept. These findings demonstrate rationale for new therapeutic strategies using a combination of AR and HDAC inhibitors to improve patient outcome in advanced stages of mCRPC.